In The Press April 28, 2020

COVID – 19 Impacting Patent Litigation, From Exclusivity Forfeiture to Launch Delays (Pink Sheet)

The COVID-19 pandemic raises a host of questions for biopharma companies engaged in patent litigation, such as whether generic manufacturers can avoid forfeiture of 180-day exclusivity and whether biosimilar sponsors might agree to delay product launches. Goodwin’s Srikanth Reddy, Elaine Blais and Daryl Wiesen discussed the challenges in navigating Hatch-Waxman and biologic litigation during the pandemic in a 23 April webinar. Read the article in Pink Sheet here